The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

PHASE3CompletedINTERVENTIONAL

Enrollment

131

Participants

Timeline

Start Date

January 21, 2022

Primary Completion Date

April 22, 2023

Study Completion Date

April 22, 2023

Conditions

Allergic Conjunctivitis

Interventions

DRUG

Reproxalap Ophthalmic Solution (0.25%)

Reproxalap Ophthalmic Solution (0.25%) dosed twice.

DRUG

Vehicle Ophthalmic Solution

Vehicle Ophthalmic Solution dosed twice.

Trial Locations (1)

Cliantha Research, Mississauga